NYSE - Delayed Quote USD

Bristol-Myers Squibb Company (BMY)

41.48 +0.60 (+1.47%)
At close: June 7 at 4:00 PM EDT
41.45 -0.03 (-0.07%)
After hours: 8:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
45,534,000.00
45,006,000.00
46,159,000.00
46,385,000.00
42,518,000.00
--
Cost of Revenue
11,059,000.00
10,693,000.00
10,137,000.00
9,940,000.00
11,773,000.00
--
Gross Profit
34,475,000.00
34,313,000.00
36,022,000.00
36,445,000.00
30,745,000.00
--
Operating Expense
27,198,000.00
26,118,000.00
26,918,000.00
27,908,000.00
28,568,000.00
--
Operating Income
7,277,000.00
8,195,000.00
9,104,000.00
8,537,000.00
2,177,000.00
--
Net Non Operating Interest Income Expense
-1,303,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
--
Other Income Expense
-11,820,000.00
1,411,000.00
-159,000.00
895,000.00
-7,628,000.00
--
Pretax Income
-5,846,000.00
8,440,000.00
7,713,000.00
8,098,000.00
-6,871,000.00
--
Tax Provision
289,000.00
400,000.00
1,368,000.00
1,084,000.00
2,124,000.00
--
Net Income Common Stockholders
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
--
Diluted NI Available to Com Stockholders
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
--
Basic EPS
-3.09
3.88
2.97
3.25
-3.99
--
Diluted EPS
-3.10
3.86
2.95
3.12
-3.99
--
Basic Average Shares
2,050,000.00
2,069,000.00
2,130,000.00
2,153,000.00
2,258,000.00
--
Diluted Average Shares
2,055,500.00
2,078,000.00
2,146,000.00
2,245,000.00
2,258,000.00
--
Total Expenses
38,257,000.00
36,811,000.00
37,055,000.00
37,848,000.00
40,341,000.00
--
Net Income from Continuing & Discontinued Operation
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
--
Normalized Income
1,676,000.00
7,997,363.00
7,439,696.00
7,213,999.51
-2,188,770.00
--
Interest Expense
1,303,000.00
1,166,000.00
1,232,000.00
1,334,000.00
1,420,000.00
--
Net Interest Income
-1,303,000.00
-1,166,000.00
-1,232,000.00
-1,334,000.00
-1,420,000.00
--
EBIT
-4,543,000.00
9,606,000.00
8,945,000.00
9,432,000.00
-5,451,000.00
--
EBITDA
5,320,000.00
19,366,000.00
19,221,000.00
20,118,000.00
4,929,000.00
--
Reconciled Cost of Revenue
10,344,000.00
9,980,000.00
9,456,000.00
9,277,000.00
11,081,000.00
--
Reconciled Depreciation
9,863,000.00
9,760,000.00
10,276,000.00
10,686,000.00
10,380,000.00
--
Net Income from Continuing Operation Net Minority Interest
-6,148,000.00
8,025,000.00
6,327,000.00
6,994,000.00
-9,015,000.00
--
Total Unusual Items Excluding Goodwill
-13,040,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
--
Total Unusual Items
-13,040,000.00
29,000.00
-1,352,000.00
-254,000.00
-9,351,000.00
--
Normalized EBITDA
18,360,000.00
19,337,000.00
20,573,000.00
20,372,000.00
14,280,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-5,216,000.00
1,363.00
-239,304.00
-34,000.49
-2,524,770.00
--
12/31/2019 - 6/1/1972

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PFE Pfizer Inc.
28.58
-0.76%
 
GILD Gilead Sciences, Inc.
64.70
+1.33%
 
ABBV AbbVie Inc.
169.42
+0.50%
 
JNJ Johnson & Johnson
147.08
+0.45%
 
MRK Merck & Co., Inc.
130.67
+0.11%
 
GSK GSK plc
41.21
-0.79%
 
AMGN Amgen Inc.
305.02
-0.22%
 
AZN AstraZeneca PLC
80.02
-1.00%
 
LLY Eli Lilly and Company
849.99
+1.52%
 
BIIB Biogen Inc.
225.43
-2.83%